Transforming vaccines with breakthrough VLP technology

Corporate profile

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes clinical and preclinical programs targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), and flu. Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

Press releases

March 30, 2023
Icosavax Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
February 28, 2023
Icosavax to Participate in the Upcoming Healthcare Conferences
February 21, 2023
Icosavax Granted FDA Fast Track Designation for IVX-A12


March 13, 2023 at 12:40 PM EDT
Oppenheimer 33rd Annual Healthcare Conference
March 7, 2023 at 9:10 AM EST
Cowen 43rd Annual Health Care Conference
December 1, 2022 at 3:55 PM EST
5th Annual Evercore ISI HealthCONx Conference

Latest presentation

January 2023
Corporate Overview
Investor Email Alerts